Revance Therapeutics, Inc.
RVNC
RVNC was delisted on the 5th of February, 2025.
86 hedge funds and large institutions have $727M invested in Revance Therapeutics, Inc. in 2017 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 37 increasing their positions, 22 reducing their positions, and 4 closing their positions.
200% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 4
68% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 22
33% more capital invested
Capital invested by funds: $546M → $727M (+$180M)
10% more funds holding
Funds holding: 78 → 86 (+8)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
15% less call options, than puts
Call options by funds: $776K | Put options by funds: $909K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
+$8.73M |
| 2 |
Jennison Associates
New York
|
+$8.44M |
| 3 |
Bank of New York Mellon
New York
|
+$5.84M |
| 4 |
JP Morgan Chase
New York
|
+$3.72M |
| 5 |
PC
PointState Capital
New York
|
+$3.61M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$8.23M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$7.53M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$3.39M |
| 4 |
Wells Fargo
San Francisco,
California
|
-$1.07M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$735K |
RVNC Hedge Fund Activity: Q2 2017 in Review
86 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Revance Therapeutics, Inc. (RVNC) for Q2 2017, worth a combined $727M — up 33% from $546M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new RVNC positions and 4 closed out — a net gain of 8 holders — while 37 added to existing stakes and 22 trimmed.
The largest buyer was Franklin Resources, adding an estimated $8.73M. The largest seller was Goldman Sachs, cutting an estimated $8.23M.
- 86 institutional investors held Revance Therapeutics, Inc. (RVNC) as of Q2 2017, up from 78 in Q1 2017.
- Funds reported $727M of Revance Therapeutics, Inc. stock for Q2 2017, up 33% quarter-over-quarter.
- 12 funds opened new Revance Therapeutics, Inc. positions in Q2 2017 and 4 closed out, a net change of +8 holders.
- The largest Revance Therapeutics, Inc. buyer in Q2 2017 was Franklin Resources, an estimated $8.73M added.
- The largest Revance Therapeutics, Inc. seller in Q2 2017 was Goldman Sachs, an estimated $8.23M sold.
Based on aggregated 13F filings for Q2 2017.